Literature DB >> 26683154

FcγRIIB and autoimmunity.

Marion Espéli1, Kenneth G C Smith2, Menna R Clatworthy2.   

Abstract

Autoimmune diseases are characterized by adaptive immune responses against self-antigens, including humoral responses resulting in the production of autoantibodies. Autoantibodies generate inflammation by activating complement and engaging Fcγ receptors (FcγRs). The inhibitory receptor FcγRIIB plays a central role in regulating the generation of autoantibodies and their effector functions, which include activation of innate immune cells and the cellular arm of the adaptive immune system, via effects on antigen presentation to CD4 T cells. Polymorphisms in FcγRIIB have been associated with susceptibility to autoimmunity but protection against infections in humans and mice. In the last few years, new mechanisms by which FcγRIIB controls the adaptive immune response have been described. Notably, FcγRIIB has been shown to regulate germinal center B cells and dendritic cell migration, with potential impact on the development of autoimmune diseases. Recent work has also highlighted the implication of FcγRIIB on the regulation of the innate immune system, via inhibition of Toll-like receptor- and complement receptor-mediated activation. This review will provide an update on the role of FcγRIIB in adaptive immune responses in autoimmunity, and then focus on their emerging function in innate immunity.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Fcγ receptors; autoantibodies; dendritic cells; germinal center B cells; lymphangiogenesis; macrophages

Mesh:

Substances:

Year:  2016        PMID: 26683154     DOI: 10.1111/imr.12368

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  32 in total

Review 1.  CD11c+ T-bet+ memory B cells: Immune maintenance during chronic infection and inflammation?

Authors:  Gary M Winslow; Amber M Papillion; Kevin J Kenderes; Russell C Levack
Journal:  Cell Immunol       Date:  2017-07-19       Impact factor: 4.868

Review 2.  Emerging Treatment Models in Rheumatology: IgG4-Related Disease: Insights Into Human Immunology and Targeted Therapies.

Authors:  Cory A Perugino; Hamid Mattoo; Vinay S Mahajan; Takashi Maehara; Zachary S Wallace; Shiv Pillai; John H Stone
Journal:  Arthritis Rheumatol       Date:  2017-08-08       Impact factor: 10.995

Review 3.  Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies.

Authors:  Juan J Mata-Molanes; Joseba Rebollo-Liceaga; Elena Mª Martínez-Navarro; Ramón González Manzano; Antonio Brugarolas; Manel Juan; Manuel Sureda
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

4.  TOM1 Regulates Neuronal Accumulation of Amyloid-β Oligomers by FcγRIIb2 Variant in Alzheimer's Disease.

Authors:  Youngdae Gwon; Tae-In Kam; Seo-Hyun Kim; Sungmin Song; Hyejin Park; Bitna Lim; Haneul Lee; Weontae Lee; Dong-Gyu Jo; Yong-Keun Jung
Journal:  J Neurosci       Date:  2018-09-05       Impact factor: 6.167

Review 5.  Role of Inflammation and Immunity in Hypertension: Recent Epidemiological, Laboratory, and Clinical Evidence.

Authors:  Antoine Caillon; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 6.  Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity.

Authors:  Kirsten M Baecher; Mandy L Ford
Journal:  Cancer Immunol Immunother       Date:  2021-07-09       Impact factor: 6.968

7.  Serine Phosphorylation of the STAT1 Transactivation Domain Promotes Autoreactive B Cell and Systemic Autoimmunity Development.

Authors:  Sathi Babu Chodisetti; Adam J Fike; Phillip P Domeier; Stephanie L Schell; Taryn E Mockus; Nicholas M Choi; Chelsea Corradetti; Baidong Hou; Hannah M Atkins; Roberto Caricchio; Thomas Decker; Aron E Lukacher; Nancy Olsen; Ziaur S M Rahman
Journal:  J Immunol       Date:  2020-04-06       Impact factor: 5.426

Review 8.  Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.

Authors:  Richard J Stopforth; Kirstie L S Cleary; Mark S Cragg
Journal:  J Clin Immunol       Date:  2016-02-27       Impact factor: 8.317

9.  Immune complex negatively regulates toll-like receptor 3-triggered tumour necrosis factor α production in B cells.

Authors:  Li Qian; Wenyan Chen; Shaoqing Wang; Yang Liu; Xiaoqin Jia; Yi Fu; Weijuan Gong; Fang Tian
Journal:  Cent Eur J Immunol       Date:  2017-10-30       Impact factor: 2.085

10.  Upregulation of FcγRIIB by resveratrol via NF-κB activation reduces B-cell numbers and ameliorates lupus.

Authors:  Jyun-Pei Jhou; Se-Jie Chen; Ho-Yin Huang; Wan-Wan Lin; Duen-Yi Huang; Shiang-Jong Tzeng
Journal:  Exp Mol Med       Date:  2017-09-29       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.